Genetics allows personalized disease predictions for chronic blood cancers

October 10, 2018, Wellcome Trust Sanger Institute
Credit: CC0 Public Domain

Scientists have developed a successful method to make truly personalised predictions of future disease outcomes for patients with certain types of chronic blood cancers. The study from the Wellcome Sanger Institute, the Wellcome-MRC Cambridge Stem Cell Institute, the University of Cambridge, and their collaborators, combined extensive genetic and clinical information to predict the prognosis for patients with myeloproliferative neoplasms. The research also identified eight different genetic subgroups of the disease that link with patterns of clinical disease and patient prognosis.

Published today in the New England Journal of Medicine, this work could lead to personalised medicine for with these . It will help doctors identify those patients who are likely to have a very good outlook, and which patients may benefit from specific treatments or clinical trials.

Myeloproliferative neoplasms are a group of cancers affecting around 30,000 patients in the UK. These cancers are chronic, long term conditions and patients suffer from a risk of blood clots and bleeding. In addition, these cancers can progress to more advanced forms of disease, including acute leukaemia, that have a poor outlook. It is important to patients to know how their disease is likely to progress in the future, but it has not previously been possible to provide personalised predictions for each individual patient.

The current classification system for these blood cancers was created in the 1950s when myeloproliferative neoplasms were divided into three clinical types. However, there are known to be challenges with this classification system. This lack of accurate classification can make it difficult for doctors to decide on the most appropriate treatment for patients and to provide information on future outlook.

To understand the biological factors causing myeloproliferative neoplasms the researchers studied 69 genes from over 2,000 patients with these blood cancers. Using this genetic information, they found there were eight different subtypes of these cancers. These genetic subtypes were also found to be clinically different from each other, indicating that the researchers had identified real differences between patient groups.

Combining the genetic information for each person with their , the researchers were then able to develop a method to make personally tailored disease predictions for individual patients suffering from these cancers. They found this personalised method outperformed all current schemes available to make disease predictions and had the additional advantage of giving patient-specific predictions, rather than simply classifying patients into broad risk categories.

Dr. Jyoti Nangalia, a first author on the study from the Wellcome Sanger Institute, said: "Despite some knowledge of the risks of myeloproliferative neoplasms we have been unable to make accurate personal predictions for individual patients. Our new online calculator takes genetic and clinical information available for a patient and makes a of the future outcome of that particular person's disease. In the future this could be used to reassure patients who have a good predicted outcome, and identify patients who are at risk of developing severe disease who could benefit from an alternative treatment approach."

Professor Tony Green, a senior author on the paper from the Wellcome-MRC Cambridge Stem Cell Institute and the University of Cambridge, Department of Haematology, said: "This work represents a step change in our understanding of the . Not only does it reveal a new classification based on causal mechanisms but it also provides for the first time personally-tailored predictions to guide patient management."

The study also revealed that some subgroups shared features with other blood cancers. This work could bring clarity to disease classification of blood cancers in the future and enable the development and testing of new treatments.

Dr. Peter Campbell, a senior author from the Wellcome Sanger Institute, said: "This research proves the potential of personalised medicine, using genetics. Modern genomics will empower clinicians and support their decisions regarding the best therapies and clinical trials for each patient. We hope our study will be a game changer for patients with these blood cancers by providing better predictions for how their may behave in the future, and inform treatment choice."

Explore further: Blood cancer patients benefit from breakthrough genetic testing service

More information: New England Journal of Medicine (2018). DOI: 10.1056/NEJMoa1716614

Related Stories

Blood cancer patients benefit from breakthrough genetic testing service

August 27, 2018
Cutting-edge DNA sequencing technology has been used by QUT researchers at the new Australian Translational Genomics Centre (ATGC) to identify genetic mutations in 100 patients with blood cancers, with this testing providing ...

Best treatment option written in cancer's genetic script: AML study finds personalised therapy is possible

January 16, 2017
An international collaboration led by clinical researchers at the Wellcome Trust Sanger Institute has shown proof-of-concept that truly personalised therapy will be possible in the future for people with cancer. Details of ...

Patients with myeloproliferative neoplasms have a significantly increased risk for arterial and venous thrombosis

January 15, 2018
Patients with myeloproliferative neoplasms (MPNs) have a significantly increased rate of arterial and venous thrombosis, with the highest rates occurring at and shortly after diagnosis. The findings of a population-based ...

Ovarian cancer genetics unravelled

August 14, 2018
Patterns of genetic mutation in ovarian cancer are helping make sense of the disease, and could be used to personalise treatment in future.

Landmark study shows Acute Myeloid Leukaemia is at least 11 different diseases

June 8, 2016
Scientists at the Wellcome Trust Sanger Institute and their international collaborators have shown that Acute Myeloid Leukaemia (AML) is not a single disorder, but at least 11 different diseases, and that genetic changes ...

Roots of leukemia reveal possibility of predicting people at risk

July 9, 2018
Scientists have discovered that it is possible to identify people at high risk of developing acute myeloid leukaemia (AML) years before diagnosis. The researchers from Wellcome Sanger Institute, European Bioinformatics Institute ...

Recommended for you

Paternal grandfather's high access to food may indicate higher mortality risk in grandsons

December 12, 2018
A paternal grandfather's access to food during his childhood is associated with mortality risk, especially cancer mortality, in his grandson, shows a large three-generational study from Stockholm University. The reason might ...

New genetic study could lead to better treatment of severe asthma

December 12, 2018
The largest-ever genetic study of people with moderate-to-severe asthma has revealed new insights into the underlying causes of the disease which could help improve its diagnosis and treatment.

Researchers use computer model to predict prostate cancer progression

December 12, 2018
An international team of cancer researchers from Denmark and Germany have used cancer patient data to develop a computer model that can predict the progression of prostate cancer. The model is currently being implemented ...

New understanding of mysterious 'hereditary swelling'

December 12, 2018
For the first time ever, biomedical researchers from Aarhus University, Denmark, report cellular defects that lead to a rare disease, hereditary angioedema (HAE), in which patients experience recurrent episodes of swelling ...

Receiving genetic information can change risk

December 11, 2018
Millions of people in the United States alone have submitted their DNA for analysis and received information that not only predicts their risk for disease but, it turns out, in some cases might also have influenced that risk, ...

HER2 mutations can cause treatment resistance in metastatic ER-positive breast cancer

December 11, 2018
Metastatic breast cancers treated with hormone therapy can become treatment-resistant when they acquire mutations in the human epidermal growth factor receptor 2 (HER2) that were not present in the original tumor, reports ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.